1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)2D3 in NSCLC Treatment

Cancers

Volumn 5, Issue 4, 2013, Pages 1504-1521

  Upadhyay, Santosh Kumar ^a   Verone, Alissa ^a   Shoemaker, Suzanne ^a   Qin, Maochun ^a   Liu, Song ^a   Campbell, Moray ^a   Hershberger, Pamela A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

1,25 dihydroxyvitamin D3; Epithelial mesenchymal transition; Lung cancer, TGF ; Vitamin D

Indexed keywords

EID: 84969313807     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers5041504     Document Type: Article

References (38)

1. Deeb, K.K.; Trump, D.L.; Johnson, C.S. Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics. Nat. Rev. Cancer 2007, 7, 684–700.
2. Schwaller, J.; Koeffler, H.P.; Niklaus, G.; Loetscher, P.; Nagel, S.; Fey, M.F.; Tobler, A. Posttranscriptional stabilization underlies p53-independent induction of p21waf1/cip1/sdi1 in differentiating human leukemic cells. J. Clin. Invest. 1995, 95, 973–979.
3. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 1996, 10, 142–153.
4. 3 on the cell cycle genes, cyclin D1, p21, and p27 in MCF-7 cells. Mol. Cell. Endocrinol. 1998, 142, 57–65.
5. 3 induces elevated expression of the cell cycle regulating genes p21 and p27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol. 2001, 121, 102–109.
6. 3 receptor. Nucleic Acids Res. 2006, 34, 543–554.
7. 3 and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 2002, 143, 2508–2514.
8. 3 . Oncogene 2008, 27, 4467–4477.
9. Chung, I.; Han, G.; Seshadri, M.; Gillard, B.M.; Yu, W.D.; Foster, B.A.; Trump, D.L.; Johnson, C.S. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res. 2009, 69, 967–975.
10. 3 and 9-cis-retinoic acid directly inhibits human telomerase reverse transcriptase transcription in prostate cancer cells. Mol. Cancer Ther. 2003, 2, 739–746.
11. 3 suppresses telomerase expression and human cancer growth through microrna-498. J. Biol. Chem. 2012, 287, 41297–41309.
12. Pereira, F.; Barbachano, A.; Silva, J.; Bonilla, F.; Campbell, M.J.; Munoz, A.; Larriba, M.J. Kdm6b/jmjd3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells. Hum. Mol. Genet. 2011, 20, 4655–4665.
13. Pereira, F.; Barbachano, A.; Singh, P.K.; Campbell, M.J.; Munoz, A.; Larriba, M.J. Vitamin D has wide regulatory effects on histone demethylase genes. Cell Cycle 2012, 11, 1081–1089.
14. Pervin, S.; Hewison, M.; Braga, M.; Tran, L.; Chun, R.; Karam, A.; Chaudhuri, G.; Norris, K.; Singh, R. Down-regulation of vitamin D receptor in mammospheres: Implications for vitamin D resistance in breast cancer and potential for combination therapy. PLoS One 2013, 8, e53287.
15. Ma, Y.; Yu, W.D.; Su, B.; Seshadri, M.; Luo, W.; Trump, D.L.; Johnson, C.S. Regulation of motility, invasion, and metastatic potential of squamous cell carcinoma by 1alpha,25-dihydroxycholecalciferol. Cancer 2013, 119, 563–574.
16. De Craene, B.; Berx, G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 2013, 13, 97–110.
17. Ren, J.; Chen, Y.; Song, H.; Chen, L.; Wang, R. Inhibition of zeb1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line. J. Cell. Biochem. 2013, 114, 1395–1403.
18. Gomez-Casal, R.; Bhattacharya, C.; Ganesh, N.; Bailey, L.; Basse, P.; Gibson, M.; Epperly, M.; Levina, V. Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes. Mol. Cancer 2013, 12, doi:10.1186/1476-4598-12-94.
19. Thomson, S.; Buck, E.; Petti, F.; Griffin, G.; Brown, E.; Ramnarine, N.; Iwata, K.K.; Gibson, N.; Haley, J.D. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005, 65, 9455–9462.
20. Witta, S.E.; Gemmill, R.M.; Hirsch, F.R.; Coldren, C.D.; Hedman, K.; Ravdel, L.; Helfrich, B.; Dziadziuszko, R.; Chan, D.C.; Sugita, M.; et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 2006, 66, 944–950.
21. Yauch, R.L.; Januario, T.; Eberhard, D.A.; Cavet, G.; Zhu, W.; Fu, L.; Pham, T.Q.; Soriano, R.; Stinson, J.; Seshagiri, S.; et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res. 2005, 11, 8686–8698.
22. Zhang, Z.; Lee, J.C.; Lin, L.; Olivas, V.; Au, V.; LaFramboise, T.; Abdel-Rahman, M.; Wang, X.; Levine, A.D.; Rho, J.K.; et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 2012, 44, 852–860.
23. Byers, L.A.; Diao, L.; Wang, J.; Saintigny, P.; Girard, L.; Peyton, M.; Shen, L.; Fan, Y.; Giri, U.; Tumula, P.K.; et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 2013, 19, 279–290.
24. 3) in non-small cell lung cancer cells with distinct oncogene mutations. J. Steroid Biochem. Mol. Biol. 2012, 136, 264–270.
25. 3 anti-proliferative signaling in lung cancer cells. Mol. Cell. Endocrinol. 2012, 355, 153–161.
26. Ramirez, A.M.; Wongtrakool, C.; Welch, T.; Steinmeyer, A.; Zugel, U.; Roman, J. Vitamin D inhibition of pro-fibrotic effects of transforming growth factor beta1 in lung fibroblasts and epithelial cells. J. Steroid Biochem. Mol. Biol. 2010, 118, 142–150.
27. Parise, R.A.; Egorin, M.J.; Kanterewicz, B.; Taimi, M.; Petkovich, M.; Lew, A.M.; Chuang, S.S.; Nichols, M.; El-Hefnawy, T.; Hershberger, P.A. Cyp24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int. J. Cancer 2006, 119, 1819–1828.
28. Xu, J.; Lamouille, S.; Derynck, R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009, 19, 156–172.
29. Kim, S.H.; Chen, G.; King, A.N.; Jeon, C.K.; Christensen, P.J.; Zhao, L.; Simpson, R.U.; Thomas, D.G.; Giordano, T.J.; Brenner, D.E.; et al. Characterization of vitamin D receptor (VDR) in lung adenocarcinoma. Lung Cancer 2012, 77, 265–271.
30. Jeong, Y.; Xie, Y.; Lee, W.; Bookout, A.L.; Girard, L.; Raso, G.; Behrens, C.; Wistuba, I.I.; Gadzar, A.F.; Minna, J.D.; et al. Research resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer. Mol. Endocrinol. 2012, 26, 1443–1454.
31. Nguyen, K.S.; Neal, J.W. First-line treatment of EGFR-mutant non-small-cell lung cancer: The role of erlotinib and other tyrosine kinase inhibitors. Biologics 2012, 6, 337–345.
32. Palmer, H.G.; Larriba, M.J.; Garcia, J.M.; Ordonez-Moran, P.; Pena, C.; Peiro, S.; Puig, I.; Rodriguez, R.; de la Fuente, R.; Bernad, A.; et al. The transcription factor snail represses vitamin D receptor expression and responsiveness in human colon cancer. Nat. Med. 2004, 10, 917–919.
33. Zhou, B.B.; Peyton, M.; He, B.; Liu, C.; Girard, L.; Caudler, E.; Lo, Y.; Baribaud, F.; Mikami, I.; Reguart, N.; et al. Targeting adam-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006, 10, 39–50.
34. Maindonald, J.; Braun, J. Data Analysis and Graphics Using R, 2nd ed.; Cambridge University Press: Cambridge, UK, 2007.
35. Creighton, C.J.; Gibbons, D.L.; Kurie, J.M. The role of epithelial-mesenchymal transition programming in invasion and metastasis: A clinical perspective. Cancer Manag. Res. 2013, 5, 187–195.
36. Kuo, C.H.; Chen, K.F.; Chou, S.H.; Huang, Y.F.; Wu, C.Y.; Cheng, D.E.; Chen, Y.W.; Yang, C.J.; Hung, J.Y.; Huang, M.S. Lung tumor associated dendritic cell-derived resistin promoted cancer progression by increasing wolf-hirschhorn syndrome candidate 1/twist pathway. Carcinogenesis 2013, doi:10.1093/carcin/bgt281.
37. Zhou, W.; Heist, R.S.; Liu, G.; Asomaning, K.; Neuberg, D.S.; Hollis, B.W.; Wain, J.C.; Lynch, T.J.; Giovannucci, E.; Su, L.; et al. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J. Clin. Oncol. 2007, 25, 479–485.
38. Zhou, W.; Suk, R.; Liu, G.; Park, S.; Neuberg, D.S.; Wain, J.C.; Lynch, T.J.; Giovannucci, E.; Christiani, D.C. Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 2303–2309.